profit from every $100 of sales.
$0$100
Atrium Therapeutics
$7.51+0.13% today
-49.1% since Feb 27, 26
1-year low $7.501-year high $16.54
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Atrium Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $9.76 million in 2023 to $18.6 million in 2025, with -$76.7 million of profit last year.
SalesProfit
Atrium Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Atrium Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Atrium Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 10 | 11 | 19 | |
| – | – | – | |
| -6 | -13 | -77 | |
| -6 | -13 | -76 | |
| -6 | -25 | -77 | |
| -0.37 | -1.47 | -2.89 | |
| – | – | – | |
| -65.4% | -121.3% | -412.6% | |
| -65.4% | -230.5% | -411.9% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 10 | 7 | 278 |
| Cash | – | – | 270 |
| Total debt | 10 | 7 | 4 |
| Total liabilities | 81 | 68 | 71 |
| -71 | -61 | 207 | |
| 17 | 17 | 17 | |
| – | – | -28.8% | |
| 9.0% | 41.1% | -37.0% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 56 | -23 | -41 | |
| 0 | 0 | 1 | |
| 56 | -23 | -43 | |
| Dividends paid | – | – | – |
| – | – | – | |
| 3 | 3 | 8 |
Valuation
- –
- –
- –
- 1.0×
- 6.9×
- –
- –
- -33.1%
- -59.7%
- 0.0%
Profitability
- 99.3%
- -412.6%
- -411.9%
- -317.4%
- -23.9%
- -36.4%
- -21.0%
- -15.7%
- -24.2%
- 171.5%
Growth
- +38.1%
- –
- –
- –
- –
Financial health
- -3.5×
- 0.01
- 0.9%
- –
- 13.04
- 13.04
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 952
Top 14%of 886
Bottom 2%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.97 | -1.05 | +7.6% |
| Feb 26, 2026 | -0.61 | -1.24 | +50.8% |
News
Atrium Therapeutics, Inc. reports Q3 resultsSeeking Alpha · Nov 13, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
69Pass
Philip Fisher
53No pass
Peter Lynch
73Pass
Joel Greenblatt
2No pass
Charlie Munger
35No pass
Terry Smith
38No pass
Questions about Atrium Therapeutics
Is Atrium Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Atrium Therapeutics AI analysis
What does Atrium Therapeutics do?
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. It is in Biotechnology.
Does Atrium Therapeutics pay a dividend?
No. Atrium Therapeutics does not pay a dividend at the moment.
Is Atrium Therapeutics stock halal?
No. Atrium Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 210% of its market value, at or above the 33% limit. How we check
Who are Atrium Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Atrium Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.